✦ LIBER ✦

1144 COMPLETE HEPATITIS C VIRUS ELIMINATION DURING PEGYLATED INTERFERON a2B AND RIBAVIRIN TREATMENT REDUCES THE RISK OF PROGRESSION TO HEPATOCELLULAR CARCINOMA

✍ Scribed by Ogawa, E.; Furusyo, N.; Kajiwara, E.; Takahashi, K.; Nomura, H.; Tanabe, Y.; Satoh, T.; Maruyama, T.; Nakamuta, M.; Kotoh, K.; Azuma, K.; Dohmen, K.; Shimoda, S.; Hayashi, J.

Book ID: 121935152
Publisher: Elsevier Science
Year: 2012
Tongue: English
Weight: 64 KB
Volume: 56
Category: Article
ISSN: 0168-8278
DOI: 10.1016/S0168-8278(12)61156-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Detection of hepatocellular carcinoma du

Detection of hepatocellular carcinoma during the treatment with pegylated interferon alfa-2a and ribavirin for chronic hepatitis C

✍ M. Capanni; E. Lorefice; M.C. Benini; M.R. Biagini; A. Tozzi; A. Galli; C. Surre 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 114 KB

Efficacy of pegylated interferon alpha-2

Efficacy of pegylated interferon alpha-2b and ribavirin treatment on the risk of hepatocellular carcinoma in patients with chronic hepatitis C: A prospective, multicenter study

✍ Ogawa, Eiichi; Furusyo, Norihiro; Kajiwara, Eiji; Takahashi, Kazuhiro; Nomura, H 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 779 KB

Hepatitis C virus RNA kinetics during th

Hepatitis C virus RNA kinetics during the initial 12 weeks treatment with pegylated interferon-alpha 2a and ribavirin according to virological response

✍ T. Carlsson; O. Reichard; G. Norkrans; J. Bläckberg; P. Sangfelt; E. Wallmark; O 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 147 KB

Variants in interferon-alpha pathway gen

Variants in interferon-alpha pathway genes and response to pegylated interferon-Alpha2a plus ribavirin for treatment of chronic hepatitis C virus infection in the hepatitis C antiviral long-term treatment against cirrhosis trial

✍ Tania Mara Welzel; Timothy R. Morgan; Herbert L. Bonkovsky; Deepa Naishadham; Ru 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 270 KB 👁 2 views

Combination treatment with pegylated-interferon-alpha (PEG IFN-␣) and ribavirin, the current recommended therapy for chronic hepatitis C virus (HCV) infection, results in a sustained virological response (SVR) in only about half of patients. Because genes involved in the interferon-alpha pathway may

Mutations in the core and NS5A region of

Mutations in the core and NS5A region of hepatitis C virus genotype 1b and correlation with response to pegylated-interferon-alpha 2b and ribavirin combination therapy

✍ K. Hayashi; Y. Katano; M. Ishigami; A. Itoh; Y. Hirooka; I. Nakano; F. Urano; K. 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 87 KB

T-46 Erythropoietin administration seems

T-46 Erythropoietin administration seems to improve the decrease in platelet count observed during pegylated interferon and ribavirin treatment of patients with hepatitis C virus-related cirrhosis

✍ E.G. Giannini; M. Basso; S. Marenco; V. Fazio; G. Pieri; V. Savarino; A. Picciot 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 45 KB